Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immune Reconstitution and Adverse Effects of ART in Advanced HIV
NCT00885664Phase 4Completed
- Sponsor
- University of Cincinnati
- Start
- Oct 2005
- Primary completion
- Sep 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of emtricitabine + tenofovir disoproxil and lopinavir + ritonavir in human immunodeficiency virus infection (HIV) (2 arms), sponsored by University of Cincinnati. Primary endpoint: Symptom Score at 4 weeks. Started Oct 2005; status: completed.
02
Drugs
emtricitabine + tenofovir disoproxillopinavir + ritonavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00885664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00885664.